chuckle.... I love this part.....
"Biotech has gone through four or five levels
of passion," Mr. Ferguson reminds us. "Then
we look back and say, 'Well, that was
interesting, but I guess it doesn't work.'
Proteomics will follow the same course -- but
we're not yet to the point where we even
know what it is that we'll be passionate
about."
Let's be realistic for a moment? There are many companies and technologies that will play a role. I don't follow Waters, CYTO, Oxford Glyco, etc. However, I do follow two-hybrid and CRGN. They will be defining, at an ever-increasing pace, useful interactions..... if one has an interest in proteomics and is not watching CRGN, one is nuts.
<g>
I encourage everyone to look at NBSC carefully. They own 80% of a biotech with vision re. partner identification, DGI BioTechnologies Inc. Moreover, the core business (the most boring forms of lab equipment) should start to attract attention as analysts start to pick "trickle down" ops in genomics (I'm hoping that BIOI fever will spread). Margins are better than 40% and sales are about 1.2X market cap. Float is about 3.2 million.
Disclaimer: I no longer own CRGN (but I'm watching it on a continuous basis for re-entry potential), but I do own NBSC and have a vested interest in its appreciation.
Good luck out there this week, all! I also feel that proteomics and other "trickle down" plays are the place to be (relative valuations). |
